Novel treatment for chromothripsis in breast cancer

• Project/Area Number: 25461978
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Nagoya University
• Principal Investigator: Tsunoda Nobuyuki 名古屋大学, 医学部附属病院, 病院講師 (40542684)
• Co-Investigator(Kenkyū-buntansha): NAGINO MASATO 名古屋大学, 医学系研究科, 教授 (20237564) ; YOKOYAMA YUKIHIRO 名古屋大学, 医学部附属病院, 講師 (80378091) ; KOKURYO TOSHIO 名古屋大学, 医学系研究科, 特任講師 (60378023)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
• Keywords: Chromothripsis

Outline of Final Research Achievements

Chromothripsis has not been identified in breast cancer and bone tumor cell lines. Anti-cancer agents are not able to induce chromothripsis in cancer cell lines, including breast, colorectal and pancreatic cancer cell lines.
Fusion genes are a genetic variation similar to chromothripsis.We identified several fusion genes, including two non-coding RNAs (LOC642236 and LOC283788). Because there are no fusion genes in normal cells, fusion genes are an appropriate target for molecular targeted therapy; therefore, novel treatment therapies involving the above fusion genes are expected in the future.